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Abstract
Background: Cerebral palsy (CP) is an upper motor neuron disease that results in a progressive movement disorder.
Secondary to the neurological insult, muscles from CP patients often become spastic. Spastic muscle is characterized by
an increased resistance to stretch, but often develops the further complication of contracture which represents a
prominent disability in children with CP. This study's purpose is to characterize alterations of spastic muscle on the
transcriptional level. Increased knowledge of spastic muscle may lead to novel therapies to improve the quality of life for
children with CP.
Method: The transcriptional profile of spastic muscles were defined in children with cerebral palsy and compared to
control patients using Affymetrix U133A chips. Expression data were verified using quantitative-PCR (QPCR) and
validated with SDS-PAGE for select genes. Significant genes were determined using a 2 × 2 ANOVA and results required
congruence between 3 preprocessing algorithms.
Results: CP patients clustered independently and 205 genes were significantly altered, covering a range of cellular
processes. Placing gene expression in the context of physiological pathways, the results demonstrated that spastic muscle
in CP adapts transcriptionally by altering extracellular matrix, fiber type, and myogenic potential. Extracellular matrix
adaptations occur primarily in the basal lamina although there is increase in fibrillar collagen components. Fiber type is
predominately fast compared to normal muscle as evidenced by contractile gene isoforms and decrease in oxidative
metabolic gene transcription, despite a paradoxical increased transcription of slow fiber pathway genes. We also found
competing pathways of fiber hypertrophy with an increase in the anabolic IGF1 gene in parallel with a paradoxical increase
in myostatin, a gene responsible for stopping muscle growth. We found evidence that excitation-contraction coupling
genes are altered in muscles from patients with CP and may be a significant component of disease.
Conclusion: This is the first transcriptional profile performed on spastic muscle of CP patients and these adaptations
were not characteristic of those observed in other disease states such as Duchenne muscular dystrophy and
immobilization-induced muscle atrophy. Further research is required to understand the mechanism of muscle adaptation
to this upper motor neuron lesion that could lead to the development of innovative therapies.
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Background
Cerebral palsy (CP) is a disorder in which children expe-
rience a non-progressive brain lesion that results in per-
manent and progressive secondary postural and
movement disorders [1]. CP has an incidence of 2.0–2.5
occurrences per 1000 live births in developed nations,
making it the most common cause of physical disability in
children [2]. There is a spectrum of disease states in CP
that affect upper and lower limbs to varying degrees. Since
the primary lesion in CP is in the central nervous system,
most CP research has been focused on the neurological
disorder [3-5]. However, since the secondary effects of CP
disrupt posture and movement, most conservative and
surgical treatments address the musculoskeletal system
[6].
It is clear that skeletal muscles from CP patients are altered
secondary to the neurological lesion. There are many neu-
rological symptoms secondary to the brain lesion includ-
ing dystonia, ataxia, athetosis and particularly spasticity
[7,8]. Loss of upper motor neuron (UMN) inhibition on
the lower motor neurons (LMN) results in spasticity,
altered muscle tone and increased/impaired motor unit
firing. Loss of UMN excitation of LMNs leads to negative
features of UMN syndrome that include weakness, fatiga-
bility, poor balance, and occasionally, sensory deficits.
Although the mechanism is unknown, spastic muscle
often shortens to create muscle contractures, which is a
primary disability of CP that leads to further complica-
tions [6]. There are many clinical approaches to managing
spasticity to increase function, potentially decrease mus-
cle contractures and most importantly improve quality of
life. Oral medications, physical therapy techniques, chem-
ical neurectomies with phenol or alcohol, chemodenerva-
tion using neurotoxins (BTX), and surgical neurectomies
have all been utilized to decrease spasticity in children
with CP [9]. Unfortunately, while there has been some
success in this management, many children ultimately
require orthopedic surgery to lengthen the tendons of
contracted muscle so that arm or leg function can be
increased. If the adaptation of the muscle tissue were
more completely understood, it might lead to novel med-
ical treatments of contractures.
Skeletal muscle from children with CP has been character-
ized at a variety of levels, with most studies reporting mus-
cle tissue and muscle fiber atrophy, decreased muscle
cross-sectional area, muscle shortening, and decreased
specific tension [10,11]. All of these changes implicate
physiological mechanisms of growth being involved in
the pathology of muscle from CP patients. Interestingly,
recent intraoperative studies of human muscles revealed
abnormally long muscle sarcomere lengths in vivo [12]
that were associated with muscle tissue of altered proper-
ties. Specifically, muscle fiber sarcomere length under no
load (i.e., slack sarcomere length) was significantly
decreased while the muscle tissue itself contained a hyper-
trophic extracellular matrix of poor material quality
[11,13]. These changes implicate the mechanical force
generating system of the muscle cell as well its extracellu-
lar matrix tissue. Muscle has been shown to adapt its
mechanical function to neurological input [14], however
the mechanism by which UMN lesion could lead to alter-
ations in muscle myogenesis, force generation, force
transmission and extracellular matrix properties is
unknown. While there is evidence that neurotrophic fac-
tors dramatically affect muscle properties [15,16], there is
neither mechanistic understanding as to how such factors
might alter tissue properties, nor information as to which
specific biosynthetic pathways might lead to these
changes.
To develop an understanding of the physiological proc-
esses altered in spastic muscle secondary to CP, we
exploited the fact that muscle tissue from a previous study,
in which the clinical severity of the spasticity was clearly
established, was available for transcriptional profiling
[17]. We used GeneChip technology to contrast the tran-
scriptome from CP patients with age-matched control
patients whose muscles were completely normal. We per-
formed a variety of analyses to identify a robust set of
genes that were significantly altered in CP and interpreted
these genes in their biological context to explain previ-
ously defined muscle changes. We also compared our
transcriptional data to two other disease states to deter-
mine whether spasticity secondary to CP results in a
unique muscle disorder at the gene expression level.
Methods
Muscle Sampling
Children were recruited for this study because they were
receiving tendon transfers of the flexor carpi ulnaris
(FCU) muscle into the extensor carpi radialis brevis
(ECRB), the extensor carpi radialis longus muscle, or the
extensor digitorum communis muscles [18]. All patients
had CP and developed a contracture indicating surgery,
despite receiving conservative treatment that included
splinting and occupational therapy. Parental consent and
child's assent was obtained in accordance with our insti-
tutional review boards. From the original sample size of
23 [18], a subset (n = 6 children, average age 12.8 ± 1.5
years) was selected to cover a range of clinical severities
determined from the House [19], Ashworth [20], and
Zancolli [21] classification systems as well as characteris-
tics of sarcomere length and range of motion. Control tis-
sue was obtained incidentally (n = 2 children, average age
8.5 ± 2.1 years) from both the FCU and ECRB muscles in
children with no previous history of any neural injury
who were undergoing surgery for forearm fracture repair.
None of the surgeries injured the control muscles in anyBMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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way. We suggest that these samples represent true muscle
controls for the following reasons: 1) the surgeon verified
that the muscles from which biopsies were taken were in
pristine condition and showed no signs of damage, 2) sur-
gery was emergent in these children, and therefore, con-
trol samples were obtained within 24 hours of fracture, 3)
controls showed no significant effect for many of the tran-
scripts associated with trauma or immobilization and
were, in fact, often altered in the opposite direction (data
not shown) (21, 60). Just prior to harvesting of the spastic
muscle biopsies, sarcomere length of the FCU was meas-
ured by laser diffraction in vivo. While the wrist was held
in neutral, a small fiber bundle was transilluminated with
a HeNe light. The sarcomere length could be calculated
from the diffraction pattern obtained [18]. CP biopsies
were snap frozen in isopentane chilled by liquid nitrogen
(-159°C), and stored at -80°C until analyzed (Table 1).
No patient had undergone serial casting prior to surgery,
two patients (AN and BF) had BTX injections into the FCU
several months prior to surgery, and one patient (AQ) had
a prior BTX injection in the biceps.
RNA preparation and gene expression profiling
RNA was extracted using a combination of standard Trizol
(Invitrogen, Carlsbad, CA) and RNeasy (Qiagen, Valencia,
CA) protocols. Briefly, 30 mg of frozen muscle was
homogenized in a rotor-stator homogenizer on ice in 0.5
ml of Trizol; 0.1 ml of chloroform was added to the solu-
tion, which was then vigorously vortexed for 15 s fol-
lowed by centrifugation at 4°C for 15 min. The upper
aqueous layer was removed and mixed with an equal vol-
ume of 70% ethanol before being added to the RNeasy
spin column. After the column was washed, it was incu-
bated with RNAse-free DNAse (Qiagen) for 15 min and
then washed again three more times before being eluted
as described in the manufacturer's protocol. RNA concen-
tration was determined by the absorbance at 260 nm, and
the 260 nm-to-280 nm absorbance ratio was calculated to
define RNA purity.
Microarray data analysis
Affymetrix microarrays ("GeneChip" HG-U133A; Affyme-
trix, Santa Clara, CA) were used for each muscle biopsy (n
= 16 chips; 2 muscles × 8 patients) and the data are avail-
able [GEO: GSE11686]. RNA processing for the Gene-
Chip, including stringent quality control measures, was
performed by the Gene Chip Core at the Department of
Veterans Affairs San Diego Health Care System, (San
Diego, CA). GeneSpring software (version 7.3; Silcon-
Genetics, Redwood City, CA) was used to identify those
genes that were significantly altered in CP. Initially, a
12.5% (2/16 chips) present call on MAS5 (Affymetrix)
was used to filter out poorly performing probe sets in the
analyses. Three independent probe set algorithms were
used for signal generation and normalization: MAS5,
RMA, and GCRMA. Recent reports support requiring con-
cordance among different probe set algorithms as an
approach to reduce false positives in data sets [22-24].
Each feature was normalized per chip (to the median of
all features on each chip) and per gene (to the median of
that feature on all chips). Normalized gene values were
subjected to a 2 × 2 Welch ANOVA of muscle type (FCU
vs. ECRB) and disease state (CP vs. CTRL) with a required
statistical significance (P < 0.05) with a Benjamini and
Hochberg False Discovery Rate (FDR) multiple testing
correction for present features. Thus 5% of the genes
deemed significant for an individual preprocessing algo-
rithm are suspected to be false positives. Features that
passed in all three preprocessing algorithms were deemed
significantly altered in CP.
The condition tree was created using a Pearson Correla-
tion similarity score and average linkage clustering algo-
rithm for all samples on present features. For severity
analysis, a Welch ANOVA for each severity parameter was
Table 1: Primers used for quantitative PCR
Gene Transcript Base pairs Sense Primer (5'-3') Antisense Primer (5'-3')
COL1A2 NM_000089 225 TCCAAAGGAGAGAGCGGTAA GCCACTTGCACCACGACTA
COL4A2 NM_001846 269 CTGGGTGGCGGAGTTTGTG GCTGATGTGTGTGCGGATGAG
COL4A3 NM_000091 157 CACCAGCTCTGATGCCAATG AGAGAAATCCAGCCGTGAGG
DMD NM_004019 151 GACCAGCACAACCTCAAGCAA TCAGCAGCCAGTTCAGACACA
FBXO32 NM_058229 376 GTCCAAAGAGTCGGCAAGT TTGGGTAACATCGGACAAGT
GAPDH NM_002046 172 TCTGACTTCAACAGCGACAC TGGTCCAGGGGTCTTACTC
IGF1 NM_000618 355 AGCAGTCTTCCAACCCAATTA CACGGACAGAGCGAGCTG
IGFBP5 NM_000599 339 CCAAACACACCCGCATCT CAGCTTCATCCCGTACTTGTC
GDF8 NM_005259 167 TATCACGCTACAACGGAAAC GGAGTCTCGACGGGTCTC
MYH1 NM_005963 132 AAGAGCAGGGAGGTTCACAC TTATCTCCAAAAGTCATAAGTACA
NEB NM_004543 131 CCGTGCCATGTATGACTATAT CGGTCCTGCCAGTCCTCTG
PVALB NM_002854 329 GATGACAGACTTGCTGAACGC CTTAGCTTTCAGCCACCAGAG
TRIM63 NM_032588 393 GAGGATTCCCGTCGAGTGAC AATGGCTCTCAGGGCGTCT
Table of primers used for QPCR analysis. Genbank accession number and PCR product length given in parentheses after each transcript nameBMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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run on the MAS5 data of the features deemed significantly
altered in CP without the control patients and a required
statistical significance of (P < 0.05) also with an FDR mul-
tiple testing correction.
Promoter sequence analysis was conducted using Gene-
Spring on the list of genes altered in CP. The upstream
sequence from -10 to -1000 base pairs was analyzed for a
nucleotide sequence of from 6 to 10 nucleotides long and
containing at most 2 N values in the middle. Significance
was determined based on the number of times the given
sequence appeared in the upstream sequence of all other
genes and was corrected for multiple testing. The analysis
was performed on the whole list of genes altered in CP
and the sub lists of up- or down-regulated.
Quantitative real-time PCR
QPCR was performed to validate expression levels of
selected genes to the GeneChip data and to provide
mRNA expression levels for genes not contained on the
HG-U133A chip. After RNA was extracted from the muscle
as described previously and diluted 1:5 with DNase/
RNase free water (Invitrogen), 1 μl of each sample was
reverse transcribed using standard protocols (Superscript
III; Invitrogen). cDNA was amplified with the Cepheid
SmartCycler (Sunnyvale, CA) with primers specific to the
genes of interest (Table 2). All primers were tested for
cross-reactivity with other transcripts using nBLAST and
Oligo (version 6.6; Molecular Biology Insights, Cascade,
CO). All samples were run at least in triplicate, along with
a standard curve. The PCR reaction vessel (25 μl) con-
tained 1× PCR buffer, 2 mM MgCl2 (Invitrogen), 0.2 mM
sense and antisense primers, 0.2 mM dNTP, 0.2×
SYBRgreen, and 1 U of platinum Taq polymerase (Invitro-
gen). Amplification conditions were as follows: An initial
hold at 95°C for 2 min was followed by 40 cycles of dena-
turing at 95°C for 15 s, followed by annealing/extension
at 68°C for 40 s. The success of each reaction was deduced
based on the observation of a single reaction product on
an agarose gel and a single peak on the DNA melting tem-
perature curve determined at the end of the reaction. To
express QPCR results, we used the standard curve method
with the "cycles to threshold" value representing the
number of PCR cycles at which the SYBRgreen signal was
increased above the threshold. Each sample's value was
measured in triplicate, normalized to the housekeeping
gene GAPDH, and then averaged. QPCR data were nor-
malized to the median value of the gene to permit com-
parison to the GeneChip data.
Myosin protein content biochemistry
Myosin heavy chain protein content was measured (Table
2) for comparison to the GeneChip data as previously
described [25]. Three bands were identified correspond-
ing to MyHC I, MyHC IIa/fetal and MyHC IIx/embryonic.
(Using this methodology, embryonic MyHC cannot be
separated from MyHC IIx and fetal MyHC cannot be sep-
arated from MyHC IIa.) The gels were scanned in a soft
laser densitometer (Molecular Dynamics Sunnyvale, CA,
USA). The relative proportion of each MyHC isoform was
determined by using a densitometric system (ImageQuant
TL Software v 2003.01, Amersham Biosciences, Uppsala,
Sweden).
Table 2: Subject information and clinical evaluations
Sub Sex Age Muscle SL (μm) House Sev Ash Zan PEFF (°) PESF (°) AEFF (°) MyHC gel
AI M1 3 F C U 6 . 3 6 1S S 4 3 - 5 - 9 0 - 7 0 x
ECRB x
AN F 12 FCU 4.56 3 SS 3 2B 50 45 -90
ECRB
AO F 11 FCU 4.01 5 SM 2 2B 65 60 -50 x
ECRB x
AQ M 15 FCU 4.01 7 M 2 2B 80 80 -50
ECRB
AT M 1 4 F C U 3 . 5 7 0 S S 3 34 54 0
ECRB
BF F 12 FCU 5.31 6 SM 3 2A 85 85 55 x
ECRB x
BP M 1 0 F C U - - C 1 09 09 09 0 x
ECRB
AZ M 7 FCU - - C 1 0 90 90 90 x
ECRB x
Table of the eight subjects used in this study with 2 muscles (FCU and ECRB) per patient with sex and age recorded. Measures of severity were 
taken to include: intraoperative measurement of sarcomere length (SL) on the FCU, House clinical assessment of activity, Severity (Sev) grouped by 
House (Severe Severe (SS), Severe Moderate (SM), Mild (M), and Control (C)), Ashworth (Ash) clinical assessment, Zancolli (Zan) classification 
based on finger extension, passive extension with flexed fingers (PEFF) passive extension with straight fingers (PESF) and active extension with 
flexed fingers (AEFF). Samples that were available for MyHC SDS-PAGE gels are noted in the final columnBMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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Gene Ontology analyses
Gene ontology analysis provides a means of converting a
list of differentially expressed genes into a hierarchical list
of gene ontologies that are significantly altered. We used
the web-based software GOTree http://bioinfo.vander
bilt.edu/gotm/; [26]) to compare the list of features
altered in CP to the list of features present on the HG-
U133A chip. In this analysis, a P-value is generated for
each ontology based on hyperbolic comparison of the
number of genes present in that list to the number of
genes expected to be present based on the size of the list.
The analysis was performed on the entire list of genes
altered in CP, with a required P < 0.01.
Biological pathway analyses
To gain understanding into the biological context of tran-
script changes, we investigated the way in which genes
were involved in various muscle pathways. We analyzed
pathways from databases including: Ingenuity Pathway
Analysis (IPA; http://www.ingenuity.com), Kyoto Ency-
clopedia of Genes and Genomes (KEGG; http://
www.genome.ad.jp/kegg/pathway.html), and Gene Map
and Pathway Profiler (GenMAPP; http://www.gen
mapp.org/). These pathways permit establishment of
pathways specific to muscle involving critical muscle
functions such as: neuromuscular junction function, exci-
tation-contraction coupling, muscle contraction, extracel-
lular matrix formation, muscle hypertrophy/atrophy,
myogenesis, and fiber type switching. Based on the path-
way databases and relying heavily our own literature
review, we created pathways specific to muscle with par-
ticular emphasis on genes altered in CP. To quantify gene
expression for pathway analysis, MAS5 data were normal-
ized to the averaged control data within each muscle type
and across CP samples. This value is termed the expres-
sion ratio.
Finally, to compare the CP transcriptome to other condi-
tions we examined the pathways specific to muscle against
transcriptome deposited for three other disease states,
Duchenne Muscular Dystrophy (DMD; GSE465; [27]),
immobilization (IMB; GSE8872; [28]), and hereditary
spastic paraplegia (HSP; GSE1300; [29]). The DMD exper-
iment used muscle from patients age 6–9 years and fur-
ther details are described in the reference [27], but we
compared data only from those U95A chipset. The IMB
experiment used medial gastrocniemus muscle from adult
patients and further details are described in the reference
[28], but we compared only data from voluntary controls
and ankle facture patients immobilized for 4–9 days. The
HSP experiment used vastus lateralis muscle from adult
patients and further details are described in the reference
[29], but we used the U133A chipset and controls (1–10)
from GSE3307. As these data sets are from subjects of dif-
ferent ages and muscles, and are acute (in the case of 4–9
days of immobilization), direct comparison to our CP
dataset is somewhat problematic; however, we are able to
investigate whether similar transcriptional trends are
present for these muscle conditions. The expression ratio
for each feature was taken as the MAS5 ratio of the average
disease state:average control state of the particular study
so disease values are normalized to their own controls.
The genes expression ratio of a pathway for each disease
(CP, DMD, IMB, HSP) was log averaged across the path-
way with inverse expression values used for inhibitors. We
similarly investigated a list of genes involved in satellite
cell states of quiescence and activation [30-32].
Results
Of the 22,283 probe sets on the HG-U133A GeneChip,
11,312 met the criteria of being "present" on 2/16 Gene-
Chips and were therefore considered for further analysis.
The number of genes that were significant for CP (P <
0.05) on the 2 × 2 Welch ANOVA of disease state and
muscle (CP vs. CTRL; flexor carpi ulnaris (FCU) vs. exten-
sor carpi radialis brevis (ECRB)) with FDR among the
three preprocessing algorithms were: 495 for Microarray
Suite Version 5.0 (MAS5), 1,141 for Robust Multiarray
Analysis (RMA), and 1,207 for GCRMA. The overlap of
these 3 preprocessing algorithms produced a final list of
205 genes (319 features) that were considered signifi-
cantly altered secondary to CP (Sup. Table 1). Of these,
more were up-regulated (143 genes, 220 features) than
down-regulated (62 genes, 99 features). Table 3 reports
the 72 genes subset of these 205 genes that were consid-
ered relevant to specific muscle functions. Genes in the
Tables (Table 1; Sup. Table 1) are reported with the P-
value for each preprocessing algorithm as well as the
expression ratio. The 2 × 2 ANOVA yielded no genes sig-
nificant (P < 0.05) for muscle type and only one gene with
a significant interaction, MYH1. This was due to control
ECRB tissue having a very low MYH1 mRNA content. This
important result supports our previous contention that,
even though these children present with wrist flexion con-
tracture, the FCU and ECRB are equally affected and the
wrist flexion simply results from the large size of the FCU
[18].
Promoter sequence analysis performed on each gene
altered in CP did not reveal any 6–10 base pair sequences
that were overrepresented 10–1000 base pairs upstream
of the gene. Of course, regulation can occur farther
upstream than 1000 base pairs and regulation sequences
can be outside of the 6–10 base pair range. Thus, further
sequence analysis may reveal significant promoter or
enhancer sequences, but none were identified using these
criteria.
Condition tree correlates with clinical severity scores and 
treatment
The condition tree resulted in the control patients being
clustered together separate from CP patients (Figure 1).BMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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Figure 1 illustrates the condition tree based on all present
genes. The tree shows that patients are grouped together in
most cases rather than by muscle type suggesting more
between-patient than between-muscle variability.
We had hoped that clinical severity [1,19-21] would allow
us to define transcriptionally, the severity of CP or differ-
ences between flexor and extensor muscles. In this way,
clinical parameters would be seen as representative of the
Table 3: Significantly altered genes in functional categories
P-Values P-Values
GENE Ratio MAS5 RMA GCRMA GENE Ratio MAS5 RMA GCRMA
Neuromuscular Junction Muscle Contraction and Structure
KCNN3 12.98 0.013 0.011 0.018 MYH1 8.57 0.001 0.001 0.000
COL4A3 2.89 0.043 0.014 0.019 MYH4 4.33 0.001 0.002 0.015
LAMB2 1.74 0.042 0.018 0.015 NEB 2.54 0.015 0.008 0.013
Excitation Contraction Coupling MYBPC2 2.16 0.027 0.004 0.004
PVALB 62.60 0.001 0.004 0.001 DMD 2.11 0.023 0.020 0.027
ATP2B2 2.60 0.033 0.023 0.021 LDB3 1.93 0.030 0.015 0.015
TRDN 2.38 0.028 0.019 0.017 Metabolism/Mitochondria Related
ATP2C1 2.30 0.046 0.047 0.041 WARS 0.64 0.044 0.040 0.019
PDE4DIP 2.10 0.005 0.003 0.004 CAV1 0.64 0.037 0.013 0.017
CALM1 1.70 0.005 0.004 0.008 CERK 0.63 0.033 0.006 0.014
CACNB1 1.51 0.045 0.014 0.017 A2M 0.62 0.015 0.016 0.010
FKBP1A 0.56 0.039 0.016 0.011 MDH1 0.60 0.050 0.017 0.011
Myogenesis/Fiber type pathways PECI 0.58 0.029 0.024 0.012
GDF8 3.65 0.025 0.032 0.007 MRPL35 0.57 0.040 0.043 0.037
IGF1 2.63 0.013 0.010 0.008 MRPS18B 0.56 0.009 0.002 0.001
IGFBP5 2.48 0.002 0.000 0.000 SLC25A20 0.55 0.044 0.049 0.022
PLCB1 2.34 0.028 0.014 0.007 CPT2 0.54 0.044 0.022 0.013
RASA4 2.26 0.037 0.027 0.029 MRPS12 0.53 0.044 0.008 0.010
PPP3CA 1.95 0.012 0.003 0.005 UCP2 0.51 0.030 0.023 0.015
PBX1 1.86 0.028 0.010 0.007 MLYCD 0.48 0.017 0.004 0.001
CALM1 1.70 0.005 0.004 0.008 PPIF 0.48 0.014 0.011 0.010
MBNL1 1.55 0.033 0.015 0.024 ADM 0.47 0.019 0.012 0.018
MEF2A 1.53 0.028 0.006 0.007 UCP3 0.47 0.014 0.010 0.007
NEO1 1.44 0.015 0.005 0.001 ALDH6A1 0.46 0.023 0.013 0.007
HMGB1 1.34 0.015 0.013 0.015 ACSL1 0.43 0.014 0.008 0.004
Extracellular Matrix GOT1 0.42 0.039 0.027 0.021
MFAP5 3.64 0.012 0.004 0.014 TST 0.41 0.015 0.002 0.001
COL4A3 2.89 0.043 0.014 0.019 MT1G 0.37 0.015 0.009 0.011
COL21A1 2.86 0.021 0.022 0.015 LPL 0.35 0.013 0.010 0.007
KAL1 2.57 0.002 0.003 0.003 RETSAT 0.35 0.002 0.006 0.005
MATN2 2.24 0.013 0.011 0.007 MT1M 0.34 0.015 0.006 0.004
CILP 2.09 0.035 0.043 0.034 MT1X 0.32 0.014 0.012 0.010
SMC3 1.88 0.021 0.026 0.019 GLUL 0.31 0.018 0.017 0.013
ECM2 1.86 0.037 0.035 0.021 MT2A 0.29 0.015 0.013 0.011
LAMB2 1.74 0.042 0.018 0.015 MT1H 0.29 0.015 0.015 0.012
COL4A1 0.51 0.048 0.032 0.015 MT1F 0.27 0.019 0.012 0.009
BSG 0.48 0.033 0.026 0.030 MT1E 0.26 0.012 0.006 0.005
COL4A2 0.43 0.012 0.010 0.006 LIPE 0.22 0.028 0.001 0.002
Table of genes within function groups related to skeletal muscle. Groups defined by ratio is the expression ratio of CP:CTRL. P-values are listed for 
the three separate preprocessing algorithms used (MAS5, RMA, GCRMA).BMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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Top: Condition tree created using Pearson Correlation for the similarity score and an average linkage clustering algorithm Figure 1
Top: Condition tree created using Pearson Correlation for the similarity score and an average linkage cluster-
ing algorithm. The tree was created based on all present features. MAS5 data were used with expression values normalized 
to each features median. Features are ordered from highest expression ratio to lowest. Bottom: Clinical conditions color-
coded with values for each sample.BMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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state of the muscle tissue. These parameters were applied
to an analysis of all of the 319 features altered in CP
(Additional File 1 Table S1) but only sarcomere length
and active wrist extension with fingers flexed had features
that were significant, containing the same two genes,
RBM9 and RHOBTB1. Heat plot of these data reveals that
even these genes undergo a much larger change in expres-
sion from the control sarcomere length (3.37 μm) to CP
sarcomere lengths than they do in CP progression (data
not shown). Thus it appears that our study is underpow-
ered to reveal transcriptional correlation with clinical
severity scores.
Treatment with BTX was investigated by comparing
injected muscles vs. non-injected CP muscles, muscle
from patients receiving injection of any muscle vs. non-
injected patient muscle, and injected FCU muscles vs.
non-injected FCU muscles. None of these analyses yielded
any genes that met our requirement for statistical signifi-
cance, and thus we show no significant transcriptional
effect of BTX injection.
RT-PCR results compared to chip results
As a quality control measure, correlation of data between
the GeneChip and QPCR was highly significant (P <
0.001) indicating internal consistency. To validate the
GeneChip data, 10 genes covering a variety of cellular
processes and expression levels were compared directly to
transcript levels determined by QPCR on the same cDNA
samples (Figure 2). For 9/10 genes studied, the direction
of the transcript change (i.e., up- or down-regulation) was
confirmed, and there was a good correlation between
methodologies in terms of the magnitude of the effect. For
two genes, (PVALB, GDF8) expression levels were evalu-
ated relative to GAPDH transcript levels. These genes were
selected based on their significant differences on the chip
and their relevance to the disease state. Significant posi-
tive correlations were observed for both genes (PVALB, r2
= 0.924, P < 0.001; GDF8, r2 = 0.864, P < 0.001). The
QPCR data were also subjected to 2 × 2 ANOVA (CP vs.
CTRL; FCU vs. ECRB) and both PVALB and GDF8 were
confirmed as significantly up-regulated in CP (Figures 3C
and 3D).
Two genes of particular interest that are related to muscle
atrophy, MAFbx (FBXO32) and MURF1 (TRIM63) were
not represented on the chip [28,33]. Their expression was
determined in the same manner as the genes described
above (Figures 3E and 3F). Both of these genes were
down-regulated in CP, but neither reached statistical sig-
nificance.
Myosin heavy chain protein-mRNA comparison
The GeneChip and QPCR provide only transcriptional
data and we wished to determine whether the transcrip-
tional changes resulted in translational changes in the
case of myosin heavy chain (MHC) for these samples
[25,34]. All of the muscles were of a mixed fiber type,
however the control ECRB tissue showed no evidence of
type 2X MHC. The spastic muscles had a higher propor-
tion of fast fibers than the controls of the corresponding
muscle, with most of the increase in type 2X MHC. Com-
parison between protein and mRNA was confounded by
the fact that MHC expression was normalized as percent
of total myosin while mRNA was normalized to the
QPCR results compared to GeneChip results for several  individual genes shown from CP (open bars) and CTRL (filled  bars) patients Figure 2
QPCR results compared to GeneChip results for sev-
eral individual genes shown from CP (open bars) and 
CTRL (filled bars) patients. Error bars represent SEM. 
QPCR data are from dilute (1:100) samples to test multiple 
genes and represent transcript level relative to total RNA (fg/
μg). GeneChip data are normalized to the median value for 
each gene and averaged across CP or CTRL samples.BMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
Page 9 of 16
(page number not for citation purposes)
median of that individual transcript across subjects. In
spite of this difference, we still expected to see the same
trend across samples, which was the case for type 1 MHC
(gene MYH8) and type 2X MHC (gene MYH1) where pro-
tein and mRNA levels were significantly correlated (Fig-
ures 4A and 4C; P < 0.05) while type 2A MHC (gene
MYH4) did not quite reach significance (Figure 4B; P =
0.065). Taken as a whole, these results suggest that, in the
case of the MHC, protein levels reflected transcript levels.
Gene ontology analysis
Thirty-eight different ontologies were overrepresented
based on the 143 up-regulated genes (Additional File 2
Table S2; Additional File 3 Figure S1). The biological proc-
esses that stood out as most relevant to the disease state
included striated muscle contraction, muscle develop-
ment, cytoskeletal anchoring, negative regulation of
metabolism, protein ubiquitination, and RNA processing.
The cellular components of these genes were generally
grouped into muscle components and ECM components,
(A/B) Sample-to-sample correlation between the QPCR and  GeneChip results Figure 3
(A/B) Sample-to-sample correlation between the 
QPCR and GeneChip results. (A) PVALB, parvalbumin; 
(B) GDF8, myostatin. The solid line is a best fit regression 
line. (C-F) QPCR results showing the difference between CP 
and CTRL patients for specific genes, (C) PVALB, (D) GDF8, 
(E) FBXO32/MaFBX/Atrogin, (F) TRIM63/MuRF. Values are 
expressed determined relative to GAPDH and normalized to 
the median value for each individual gene. (*) represents sig-
nificant difference (P < 0.05). Error bars represent SEM.
Comparison of the GeneChip mRNA data to protein SDS- PAGE gel data for three myosin heavy chains commonly  expressed in human skeletal muscle Figure 4
Comparison of the GeneChip mRNA data to protein 
SDS-PAGE gel data for three myosin heavy chains 
commonly expressed in human skeletal muscle. A: 
Type 1 MHC (MYH6), B: Type 2A MHC (MYH2), C: Type 
2X MHC (MYH1). mRNA data are normalized to the median 
value for each gene on the chip using MAS5 preprocessing 
and protein data are normalized to total MyHC content.BMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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particularly the basement membrane. Twenty-eight differ-
ent ontogenies were overrepresented based on the 99
down-regulated genes (Additional File 4 Table S3; Addi-
tional File 5 Figure S2). The two major functions of the
down-regulated biological processes were fatty acid
metabolism and transport. This corresponded with the
molecular function ontologies involved in fatty acid/acyl
CoA binding and also contained cadmium and copper
ion binding. Cellular component categories were almost
exclusively related to the mitochondria, however it was
interesting that sheet forming collagen type IV of the base-
ment membrane also was over represented using this ana-
lytical approach.
Gene pathways related to muscle function
To understand muscle tissue adaptation to CP from a
physiological perspective, we analyzed gene expression
ratio patterns within muscle-specific pathways of gene
products that interact in a given muscle function.
Because CP is a neurological disorder, a pathway describ-
ing the neuromuscular junction (NMJ) was created (NMJ;
Figure 5A). No postsynaptic genes were significantly
altered in CP including subunits of the nACHR receptor.
Collagen type IV subunits (COL4A3; 2.89 and COL4A4;
3.26) and laminin (LAMB2; 1.74) of the synaptic basal
lamina were significantly up-regulated. A Ca2+-activated
K+ channel (KCNN3; 12.98), was dramatically up-regu-
lated in CP.
The process of converting the action potential into muscle
contraction is referred to as excitation-contraction cou-
pling (ECC; Figure 5B). The β1 regulatory subunit of the
L-type voltage gated Ca2+ channel was significantly up-reg-
ulated in CP (CACNB1; 1.59). Although the ryanodine
receptor responsible for releasing Ca2+ from the sarcoplas-
mic reticulum (SR) was not altered, the genes FKBP1A
(0.56) and PDE4D (0.68) that prevent channel leaking,
were significantly down-regulated [35]. Myomegalin
(PDE4DIP; 2.10) was altered significantly in CP and is
thought to anchor PDE4D near the SR [36]. Calmodulin
(CALM1; 1.70) was significantly up-regulated. The most
drastic change with CP on gene expression was in the up-
regulation of muscle-relaxing protein, parvalbumin
(PVALB; 62.6). The process of pumping Ca2+ back into the
SR is assisted by triadin (TRDN; 2.39), which was signifi-
cantly up-regulated.
Pathways specific to muscle analysis of transcription in CP muscle Figure 5
Pathways specific to muscle analysis of transcription in CP muscle. Pathways A-G involved in muscle function. 
Color is determined by the expression ratio. Up-regulated genes are red and down-regulated genes are green. Green connec-
tors represent activation and red connectors represent inhibition in the direction of the arrow. Bolded genes represent those 
that are significantly altered in all three preprocessing algorithms. Italic genes (RAS, MAPK) are sets of genes involved in muscle 
MAPK pathway in muscle, but are not colored by expression because many individual genes are applicable and not altered in 
CP. Pathways represented are A: NMJ, B: ECC, C: MC, D: ECM, E: MYG, F: FT, and G: IGF1.BMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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Muscle contraction obviously requires the myosin heavy
chain motor and a cytoskeletal framework (MC; Figure
5C). MYH1 (type 2X MHC; 8.57) was significantly up-reg-
ulated in CP along with MYH4 (type 2B MHC; 4.33) a
gene not normally expressed in humans [37]. The devel-
opmental MHCs, MYH3 (embryonic MHC; 15.74) and
MYH8 (perinatal MHC; 7.74) showed large up-regulation.
MYH7 (type 1 MHC; 0.72) was unchanged. The MYBPC2
(2.16) is a fast isoform of myosin binding protein and was
up-regulated in CP. Several sarcomeric structural compo-
nents were also up-regulated as well: dystrophin (DMD;
2.11), nebulin (NEB; 2.54), and muscle LIM domain
binding protein 3 (LDB3; 1.93).
We suspected that ECM transcription would be altered
based on previous biomechanical results ([11,13,38];
ECM; Figure 5D). Fibrillar collagens all increased mod-
estly. Interestingly, basal laminar collagen IV was altered
with COL4A1 (0.51) and COL4A2 (0.43) decreasing sig-
nificantly while COL4A3  (2.89) and COL4A4  (3.26)
increased significantly. Basigin, (BSG; 0.48) was signifi-
cantly down-regulated. Various other ECM components
were also up-regulated in CP: ECM2 (1.86), KAL1 (2.57),
MATN2 (2.24), MFAP5 (3.64), CILP (2.09) and SMC3
(1.88).
Myogenesis describes the pathway that produces muscle
growth (MYG; Figure 5E). IGF1 (2.63) was up-regulated
along with IGFBP5 (2.48) (IGF1; Figure 5F). Myostatin
(GDF8; 3.65), an inhibitor of myogenesis, was also signif-
icantly up-regulated. Other significantly up-regulated
genes implicated in myogenesis are NEO1 (1.44, [39]),
PLCB1 (2.34, [40]), PBX1 (1.86, [41]), and HMGB1 (1.65,
[42]),  MBNL1  (1.74, [43]), and MAPK6 (1.77, [44]).
However, the muscle regulatory factors (MYOD1  1.22;
MYF6 0.87; MYF5 1.06; MYOG 1.75) did not show a sig-
nificant transcriptional change. Mitogen activated protein
kinases (MAPK) have been proposed as a major pathway
in muscle hypertrophy [45], however our study showed
minimal transcriptional affects on this signaling family.
Another segment of myogenesis relates to satellite cell
activation, proliferation and incorporation into adult
muscle fibers. None of the markers for quiescent or acti-
vated satellite cells (quiescence: PAX7,  FOXK1,  MET,
CDH15,  NCAM1,  VCAM1,  SDC3,  SDC4; activation:
MYF5, MYOD1, MYOG, MYF6, PCNA, CDKN1A, MYH3,
MYH8) were significantly altered in CP suggesting mini-
mal involvement of satellite cells in the disease. Addi-
tional cell cycle transcripts were investigated, but did not
show a significant change.
Although slow fiber creation is related to myogenesis,
there is also a specific pathway for slow oxidative muscle
fiber type determination (FT; Figure 5F). Sensing and sig-
naling factors, CALM1 (1.70) and calcineurin (PPP3CA;
1.95) respectively, had significantly increased transcrip-
tion along with transcription factor MEF2A (1.53), but
NFATs and other MEF2 expressions levels were
unchanged.
Cerebral palsy compared to other muscle pathologies
To determine whether the CP transcriptome was unique
or simply a secondary adaptation of decreased activity in
these children (as might be observed with immobilization
(IMB)), or whether the response was a generic muscle
pathology (Duchenne Muscular Dystrophy (DMD) being
the most-commonly studied), or was similar to spastic
muscle in an alternative more developed muscle (Heredi-
tary Spastic Paraplegia (HSP) being a spastic condition
with adult subjects) we compared our GeneChip data to
these three muscle pathologies for which GeneChip data
were available [27-29]. To make these comparisons, the
expression ratio values for the pathways were compared
amongst the three conditions (Table 4). While averaging
over an entire pathway may be misleading (similar scores
may result from different gene expression patterns), differ-
ent scores do emphasize pathways that are unique among
disease states. This analysis revealed significant satellite
cell activation, as expected, in DMD [27] as well as
increased NMJ components (primarily nicotinic acetyl-
choline receptor subunits) and loss of contractile material
as expected in IMB [28]. HSP represents muscle adapta-
tion to altered neuronal input, although there was a neg-
ative correlation in most pathways, ECC seemed to be
handled in a similar manner. CP was unique relative to
the other two pathologies based on the IGF1 pathway
increase, slow fiber activation, and increased expression of
ECC activators and inhibitors. Thus, the correlation data
support the assertion that CP is unique relative to other
disease states.
Table 4: Changes in pathways correlated with other muscle 
disease states
CP DMD IMB HSP
MEAN MEAN CORR MEAN CORR MEAN CORR
NMJ 2.39 0.98 -0.24 1.19 -0.05 0.97 -0.02
ECC 0.66 0.90 0.12 1.26 0.14 1.39 0.62
MC 2.91 2.18 0.91 0.65 -0.74 1.07 -0.48
ECM 1.63 1.73 -0.23 0.69 0.44 0.66 0.02
FT 1.35 0.70 -0.21 0.92 0.37 0.91 -0.79
IGF1 1.19 1.58 N/A 1.04 N/A 0.76 N/A
MYG 1.14 1.11 -0.16 1.01 -0.24 1.01 -0.09
SCQ 1.19 1.18 -0.67 1.11 0.66 1.23 0.07
SCA 2.17 3.73 0.91 0.86 -0.81 0.94 -0.54
Quantification of gene pathways in various disease states (CP, DMD, 
IMB, HSP). Quantification represents MEAN (geometric mean of 
expression ratios in specific muscle pathways defined in Figure 5 using 
inverse values for pathway inhibitors) and CORR (correlation of CP 
with the other disease states, reported with an R value). Satellite cells 
markers are separated into genes expressed in the quiescent (SCQ) 
and activated states (SCA).BMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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Discussion
The purpose of this study was to define the muscle tran-
scriptional adaptations in children with cerebral palsy
(CP) to gain insights into the cellular mechanisms that
might explain muscular adaptation in this neurological
condition. We show that the transcriptional profile of CP
muscle is fundamentally different compared to normal
controls (Figure 1). Previous CP muscle studies of intra-
operative sarcomere length [12], in vitro tissue biome-
chanics [38,46], and immunohistochemical and
biochemical assays suggested adaptation of extracellular
matrix regulation [11,13], myogenenic pathways [10,38],
and fiber type determination pathways [25] in this condi-
tion. Our transcriptional analyses provide potential expla-
nations of the cellular bases for these adaptations. Based
on a general understanding of muscle physiology and
biology, we placed the gene expression patterns into the
context of six major muscle physiological systems – the
neuromuscular junction (Figure 5A), excitation-contrac-
tion coupling (Figure 5B), muscle contraction (Figure
5C), extracellular matrix regulation (Figure 5D), myogen-
esis (Figure 5E) and fiber type determination (Figure 5F).
As will be seen, one feature of CP is that conflicting ten-
dencies occur within and between these various systems.
The initial insult in CP is located in the central nervous
system, but this primary insult leads to a secondary effect
on the skeletal muscle system. Thus the NMJ, as the nerve-
muscle interface, may play a role in CP. Studies have
shown disrupted NMJ in that acetylcholine receptors
appear outside the NMJ area more often in CP, although
they were unable to find any change in transcriptional reg-
ulation [47,48]. However, KCNN3 was the 2nd most up-
regulated gene on the entire chip and this gene plays a role
in causing after-hyperpolarizations which may be a cellu-
lar attempt to limit the excessive motor unit firing that has
been reported in spastic muscle [49]. Interestingly,
KCNN3  is usually expressed in immature muscle and
inhibited after innervation, which may indicate a sort of
"immature state" of this muscle [50]. Although their local-
ization in these samples is unknown the standard colla-
genous component of the synaptic basal lamina
(COL4A3; COL4A4) was transcriptionally increased, the
opposite activity of primary muscle basal lamina colla-
gens (COL4A1; COL4A2) [51]. If these synaptic collagen
IV subunits occurred outside the NMJ it would suggest a
further degree of NMJ disorganization, alternatively they
could be another indicator of muscle in an "immature
state."
We also uncovered significant evidence of altered calcium
handling secondary to CP. Our data appear to reflect
chronically increased intracellular calcium since the L-
type voltage gated Ca2+ channel (CACNB1) was up-regu-
lated (leading to activation of the ryanodine receptor) and
leakage through the ryanodine receptor would be
increased by down-regulation of two genes that prevent
leakage (FKBP1A;  PDE4D). Another "attempt" by the
muscle to re-regulate [Ca]i can be inferred by the up-regu-
lation of TRDN, which reclaims Ca2+ to the SR by localiz-
ing calsequestrin within the SR [52]. Chronically altered
calcium levels and subsequent activation of the intramus-
cular calcium-activated proteases (Calpains) would cause
dramatic muscle lesions, although they are not transcrip-
tionally regulated in CP. Indeed, a relatively new class of
Calpain-mediated myopathies has recently been
described [53,54]. Perhaps in response to this chronic
change in [Ca]i a huge 63-fold increase in PVALB, a Ca2+
binding protein was induced in order to force muscle
relaxation [55]. This dramatic adaptation could have sig-
nificant effects on the [Ca]I and may even lower it below
control levels and alter muscle contractile properties.
Of the proteins involved in calcium induced force genera-
tion, MHC isoforms are the most responsive to CP. They
are primarily responsible for determining muscle fibers
type [56] and undergo a transformation in the direction of
a slow-to-fast phenotype. This shift included immature
myosins, which saw large increases, although they were
only significant in 2/3 algorithms, and lends further evi-
dence to muscle in an "immature state." The many oxida-
tive metabolic genes that are down-regulated in CP (Table
3) support this slow-to-fast transition. The ontology anal-
ysis revealed the loss of metabolic and mitochondrial
related transcripts represented the majority of down regu-
lated ontologies (Additional File 4 Table S3). Although
previous research is mixed on whether spastic muscles
become more fast or slow, our data is in concordance with
recent research that fast fibers dominate spastic muscle in
CP [25,34]. Paradoxically, this transformation occurs
despite an overall increase in gene transcription related to
the determination of the slow fiber phenotype, particu-
larly calmodulin (CALM1) and calcineurin (PPP3CA)
[57]. A potential explanation may be that the dramatic
PVALB expression actually leads to a decrease in intracel-
lular calcium, thus turning off the initiation of the slow
gene program. The validity of the calcineurin/NFAT path-
way for transcription of a slow muscle fiber program has
also come under question [58,59].
The slow fiber program represents only one segment of
myogenesis that is controlled by many other genes. While
the majority of the pathway elements (receptors, second
messengers, signaling molecules) involved in myogenesis
were not changed, two of the most important initial fac-
tors were both up-regulated – insulin-like growth factor
(IGF1) and myostatin (GDF8). Interestingly they produce
opposing effects on myogenesis with IGF1 leading to
hypertrophy and myostatin opposing growth [60,61].
What this means for the net level of myogenesis is unclear.BMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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Satellite cells are an important contributor to muscle
growth, but their role in CP is difficult for us to discern as
neither quiescent nor activated satellite cell markers were
altered transcriptionally.
Muscle development was indicated in the ontology analy-
sis (Additional File 2 Table S2) and some genes related to
myogenesis were up-regulated (Table 3). While the mus-
cle regulatory factors were not significantly altered, appar-
ently fewer "growth" proteins must be activated since
muscle growth in children with CP is decreased [10]. The
reduction of parallel growth would lead to decreased mus-
cle strength in CP patients. Reduced longitudinal growth
would limit range of motion, and this has been suggested
as the cause for extraordinarily long in vivo sarcomere
lengths in children with wrist flexion contractures [12].
The increase in GDF8 could be responsible for this lack of
growth in spastic CP muscle and thus represent a potential
therapeutic target. Other evidence pointing toward mus-
cle degradation is in the expression ontology of protein
ubiquitination being increased, based on the up-regula-
tion of 4 related genes (FBXO3,  PCNP,  RBBP6, and
UBE2V2) and supported by an up-regulation of CACYBP,
a gene involved in calcium dependent ubiquitination. The
opposing actions of IGF1 to increase muscle mass are also
controlled by a number of IGF binding proteins and we
revealed  IGFBP5  was significantly up-regulated in CP,
however the effects of IGFBP5 in muscle have been ques-
tioned [62,63]. These results make the activation of the
IGF1 pathway difficult to decipher at the transcriptional
level. Furthermore, the hypertrophic effect of IGF1 is pri-
marily from an increase in translation efficiency, which
could have broad effects but would be unobservable in
our study.
One of IGF1's broad anabolic effects could be a contribu-
tion to the increased ECM in muscle from CP patients
[64,65]. While the ECM is altered transcriptionally, it is
unclear which components are most affected. The fibrillar
components of collagen in muscle are primarily collagen
types I and III and each alpha chain of these collagen types
were slightly up-regulated. The most dramatic changes
were in the collagens of the basal lamina discussed in ref-
erence to the NMJ. Overall the basal lamina has been
demonstrated as an area of excessive growth, and thus
may be important in understanding muscle pathology
[13]. Gene ontology analysis revealed a set of genes asso-
ciated with the ECM that were all significantly up-regu-
lated (Additional File 2 Table S2). This supports the
hypothesis of a prolific ECM in spastic muscle of CP
patients. The decreased transcription of basigin (BSG;
0.48) could also lead to extensive ECM through the
reduced activation of MMPs [66]. Basigin may also impli-
cate a disorganized ECM lacking full functionality as MMP
activity is usually increased along with increases in ECM
production. However TIMP's are the primary MMP inhib-
itors and did not show a corresponding transcriptional
increase [67].
It is important to note the distinct pathology of CP, as
spastic muscle does not fit neatly into any of the other
"altered use" muscle models [68]. The transcriptional con-
trol of muscle in CP was qualitatively different compared
to DMD, IMB, or HSP (Table 4). DMD actually showed
the most similarity to CP, particularly among contractile
genes and satellite cell markers. DMD is known to have
activated satellite cells and regenerating muscle and this
correlation implicates the same in CP, although no satel-
lite cell activation markers were significantly up-regulated
in CP. IMB and HSP had an opposing effect on satellite
cells, which shows this is not consistent with all disease
states. IMB has been shown to result in muscle atrophy,
fibrosis, and a shift from slow to fast muscle fibers.
Although we were not able to compare our results to a
human overactivity microarray study we clearly did not
show the increase in slow fibers and mitochondrial tran-
scripts expected. In fact HSP, which may be expected to
the most similar to CP, resulted in little correlation (R <
0.1) with CP in all pathways except ECC. This suggests
that ECC alterations may be a defining characteristic of
spastic muscle. It is also interesting to note that, in the
other cases, IGF1 and GDF8 acted alternatively – IGF1
increased while GDF8 decreased in DMD and conversely
for IMB and HSP. This highlights the unique adaptation of
CP, where myogenesis is turned on and off simultane-
ously.
While we are able to demonstrate the transcriptional
effects of CP we also investigated this effect on two sepa-
rate muscles and at different levels of clinical severity. Ten-
don transfer surgery is relatively common procedure for
CP patients and is implicated when there is a muscular
imbalance around a joint. It involves transferring the dis-
tal tendon of a muscle on the side of a joint considered to
have a contracture or relative over activity to a tendon on
the opposing side of the joint. Transfer of FCU to ECRB to
correct wrist position is one of the common tendon trans-
fer surgeries. Thus FCU is considered the more pathologic
muscle and we might have expected a different transcrip-
tional profile. However, we were unable to show any tran-
scriptional differences between the muscles, indicating
that both wrist flexors and extensors have a similar adap-
tation to CP. While the FCU is known to exhibit contrac-
tures in CP, we conclude that the contracture is developed
due to its architecture, not due to a fundamental differ-
ence is secondary adaptation to the altered neuronal input
of CP. The FCU is a larger muscle than the ECRB and the
larger wrist flexor muscles may simply dominate the dis-
ease state based on their size. We were also unable to show
significant transcriptional differences among various clin-
ical severity scores in CP patients. This may be because CP
transcriptional profiles are either on or off. More likelyBMC Medical Genomics 2009, 2:44 http://www.biomedcentral.com/1755-8794/2/44
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our study was unable to resolve a severity effect as the
study is biased towards the most severe cases (patients
recruited based on corrective surgery) or the study is sim-
ply underpowered. We would likely need more patients
across the range of clinical severity scores to define the
genes most closely correlated with severity. However the
low power of the severity analysis is increased in our com-
parisons of CP vs. control muscle. Further, a discussion of
statistical power does not apply to significant differences
detected in CP vs. control muscle. We do acknowledge,
however, that we are clearly not detecting all transcripts
that are altered in CP.
Our study has some inherent limitations, one of which is
the small sample size noted above, especially in the case
of control patients. As with any human study there is a
high degree of heterogeneity among the samples. These
patients have been treated in a variety of ways, and it is
important to note that our transcriptional profile is not
solely based on CP, but includes conservative treatment.
We must also point out that this muscle is in a chronic dis-
ease state, making it difficult to discern the primary effects
of CP from compensatory mechanisms that have taken
place. As with any GeneChip study, we discuss only tran-
scriptional control and any observation is subject to post-
transcriptional modification.
Despite these inherent limitations we have been able to
highlight areas where future work on spastic CP muscle
may lead to innovative therapies. Our altered calcium
handling data points to chronically elevated calcium lev-
els which are highly dangerous since they may activate
endogenous proteases. Fortunately a variety of calcium
channel blockers have been developed and tested which
could be of use in treating CP. Another potential applica-
tion of current techniques could come from antifibrotic
therapy to combat the increase in ECM components
which is suggested by the transcriptomes. Of the most
promising may be myostatin inhibiters, currently under
investigation, since growth is inhibited in muscle from CP
patients and myostatin, a major inhibiter of muscle
growth is significantly up-regulated. This transcriptional
study helps point the way to these and other areas of pro-
tein modifications, cell signaling, and biomechanics
where future investigations should be focused.
Conclusion
Dramatic transcriptional alterations occur in muscle sec-
ondary to CP. These transcriptional changes ultimately
lead to derangement of the ECM components of spastic
muscle along with alteration of transcripts involved in
myogenesis. A number of genes alter their expression in
order to create a slow-to-fast transition of MHC isoforms
and metabolic profile. GeneChip analysis has also
allowed us to demonstrate the many changes in Ca2+ han-
dling occur in CP that was not suggested previously.
Together we are able to postulate the mechanisms known
to affect muscle function in CP and predict new ones. This
will aid future research into CP muscle and therapies to
treat CP patients.
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